US biosimilar guidance: broader population permitted, more immunogenicity requested
This article was originally published in SRA
Executive Summary
Final biosimilars guidance from the US Food and Drug Administration gives sponsors more information about how to bridge data, extrapolate from one condition, choose a study population, and conduct immunogenicity testing. These documents, together with an additional draft guidance, offer pros and cons for sponsors of biosimilar applications and provide substantial additional details on the agency’s regulatory approach to such products.
You may also be interested in...
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.
Off-Label Communication: Industry Opposes Exclusion Of Phase II Data From US FDA’s Guidance
Revised draft guidance about scientific information on unapproved uses (SIUU) of medical products is “impermissibly paternalistic and overly restrictive of scientific speech,” MIWG says.